skip to content


Issue No. 14 | June 20, 2014

News and Features

June 27 is National HIV Testing Day

According to the Centers for Disease Control and Prevention (CDC), about 50,000 people get infected with HIV each year in the United States. However, 1 in 6 people living with HIV don’t know that they are infected. National HIV Testing Day is observed each year on June 27 to highlight the importance of HIV testing.

CDC recommends that everyone between the ages of 13 and 64 get tested for HIV at least once as part of their routine health care. Regardless of age, people at high risk of HIV should get tested more often.

Visit the AIDSinfo National HIV Testing Day webpage [en español] to learn more about HIV testing and to find a testing center near you.

Changes to the Complera (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate) Labeling

"On June 5, 2014, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) fixed-dose combination tablet labeling to include rilpivirine dose adjustment information when Complera is coadministered with rifabutin."

The updated labeling for Complera is available at the FDA website.

More information is available:

New Pediatric Dosage Form and Label Changes for Reyataz (Atazanavir)

"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label."

The updated labeling for atazanavir is available at the FDA website.

More information is available: